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To the Editor: Recently, we read with interest and pleasure
Coca et al.’s1 systematic review of the accuracy and reliability
of serum and urinary biomarkers for the diagnosis and risk
stratification of acute kidney injury (AKI). One of Coca
et al.’s findings is that serum cystatin C (CysC) performed
best for early as well as differential diagnosis of established
AKI.
Timing for the detection of early-stage renal impairment
is extremely important, especially in the therapeutic manage-
ment of complex illness. In an acute condition, the absence of
a reliable biomarker and the reliance on serum Cr (sCr)
markedly delays the diagnosis and, consequently, the
institution of therapy. Recently, research interest on the role
of serum CysC in an intensive care unit (ICU) population has
been stopped after the presumed association of CysC with
inflammatory biomarkers in non-critically ill patients.2
We retrospectively reviewed all laboratory data referral to
1000 patients (611 mean, mean age 64.3 years) admitted in
the ICU or the post-cardiac surgery intensive care unit
(PCSICU). PCSICU population was submitted to extra-
corporeal circulation during cardiac surgical intervention. A
total of 3993 samples tested contemporaneously for sCr,
CysC and C-reactive protein (CRP) were selected (Table 1).
Renal replacement therapy and known thyreopathy were
exclusion criteria. No correlations between CysC vs CRP and
sCr vs CRP were found either in ICU or in PCSICU.
Moreover, we observed a well-known correlation between sCr
and CysC in our entire population (r¼ 0.739, Po0.01). Our
results are encouraging for the resumption of the use of CysC
for monitoring renal function in critically ill patients. Large
multicenter studies in ICU populations are needed for
definitive approval or not of serum CysC in early AKI
diagnosis.
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We read with interest the letter in response to our
systematic review and the new data from Ferrannini
et al.,1 which demonstrates that serum cystatin C is not
correlated with C-reactive protein and is strongly corre-
lated with serum creatinine. We agree that more studies
investigating the utility of serum cystatin C in acute
kidney injury (AKI) for critically ill patients should be
conducted.
It is important, however, to not just correlate cystatin C
concentration with serum creatinine concentration, as was
presented in the study. The objective of the novel
biomarker studies should be to replace serum creatinine
or strengthen the current diagnostic and prognostic
assessment along with serum creatinine. Thus, it is
important to design studies and perform analyses, that
would delineate other attributes of the new diagnostic tool
rather than mimicking the diagnostic abilities of serum
creatinine. For example, a study by Herget-Rosenthal
et al.,2 demonstrated that the rise in serum cystatin C
preceded the rise in serum creatinine by 1.5±0.6 days.
This study also compared the performance of cystatin C
against clinically meaningful end points, including the
RIFLE definitions for AKI and dialysis-requiring AKI.
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Table 1 | Mean and standard deviation (s.d.) of age, sCr, CysC
and C-reactive protein (CRP) in our ICU population
Age
(years)
Cystatin C
(0.55–0.95 mg/l)
CRP (o5 mg/
100 ml)
Creatinine
(0.7–1.2 mg/100 ml)
Women
N 1662 1662 1662 1661
Mean 65.4 1.94 102.8 0.97
s.d. 16.1 1.14 95.5 0.75
Men
N 2331 2331 2331 2328
Mean 58.9 1.786 105.7 1.16
s.d. 18.1 1.08 97.7 1.10
Total
N 3993 3993 3993 3989
Mean 61.6 1.85 104.5 1.08
s.d. 17.6 1.10 96.8 0.97
CysC, cystatin C; ICU, intensive care unit; sCr, serum Cr.
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